122 related articles for article (PubMed ID: 25265352)
1. Increase of antitumor activity of cisplatin using agonist of gonadotropin-realising hormone and inhibitor of aromatase on the model of ascites ovarian tumor.
Tkalia IG; Vorobyova LI; Grabovoy AN; Svintsitsky VS; Tarasova TO; Lukyanova NY; Todor IN; Chekhun VF
Exp Oncol; 2014 Sep; 36(3):184-90. PubMed ID: 25265352
[TBL] [Abstract][Full Text] [Related]
2. The antitumor efficacy of cisplatin in combination with triptorelin and exemestane therapy for an ovarian cancer ascites model in Wistar rats.
Tkalia IG; Vorobyova LI; Grabovoy AN; Svintsitsky VS; Tarasova TO
Exp Oncol; 2015 Mar; 37(1):30-5. PubMed ID: 25804228
[TBL] [Abstract][Full Text] [Related]
3. Influence of gonadotropin-releasing hormone agonist on the effect of chemotherapy upon ovarian cancer and the prevention of chemotherapy-induced ovarian damage: an experimental study with nu/nu athymic mice.
Lin QY; Wang YF; Weng HN; Sheng XJ; Jiang QP; Yang ZY
J Zhejiang Univ Sci B; 2012 Nov; 13(11):894-903. PubMed ID: 23125082
[TBL] [Abstract][Full Text] [Related]
4. [Antitumor activity of dioxadet compared with cisplatin on ascitic ovarian tumor in rats].
Bespalov VG; Beliaeva OA; Panchenko AV; Stukov AN; Gershanovich ML; Murazov IaG; Kon'kov SA; Kil'maeva NE; Krylova IM; Mironiuk TA; Latipova DKh
Vopr Onkol; 2011; 57(6):771-4. PubMed ID: 22416396
[TBL] [Abstract][Full Text] [Related]
5. [Effect of gonadotropin-releasing hormone-I agonist and gonadotropin-releasing hormone-II on endometrial carcinoma cell lines with different states of PTEN].
Zhao LJ; Wei LH; Li XP; Wang JL
Zhonghua Fu Chan Ke Za Zhi; 2009 Jan; 44(1):45-9. PubMed ID: 19563062
[TBL] [Abstract][Full Text] [Related]
6. Gonadotropin-releasing hormone (GnRH) agonist triptorelin inhibits estradiol-induced serum response element (SRE) activation and c-fos expression in human endometrial, ovarian and breast cancer cells.
Gründker C; Günthert AR; Hellriegel M; Emons G
Eur J Endocrinol; 2004 Nov; 151(5):619-28. PubMed ID: 15538941
[TBL] [Abstract][Full Text] [Related]
7. Receptors for luteinizing hormone-releasing hormone (GnRH) as therapeutic targets in triple negative breast cancers (TNBC).
Kwok CW; Treeck O; Buchholz S; Seitz S; Ortmann O; Engel JB
Target Oncol; 2015 Sep; 10(3):365-73. PubMed ID: 25293576
[TBL] [Abstract][Full Text] [Related]
8. Comparative Study of Antitumor Efficiency of Intraperitoneal and Intravenous Cytostatics in Experimental Rats with Disseminated Ovarian Cancer.
Bespalov VG; Vyshinskaya EA; Vasil'eva IN; Semenov AL; Maidin MA; Barakova NV; Stukov AN
Bull Exp Biol Med; 2017 Jan; 162(3):383-386. PubMed ID: 28091920
[TBL] [Abstract][Full Text] [Related]
9. Estrogen suppression in premenopausal women following 8 weeks of treatment with exemestane and triptorelin versus triptorelin alone.
Jannuzzo MG; Di Salle E; Spinelli R; Pirotta N; Buchan P; Bello A
Breast Cancer Res Treat; 2009 Feb; 113(3):491-9. PubMed ID: 18330698
[TBL] [Abstract][Full Text] [Related]
10. Comparative efficacy evaluation of catheter intraperitoneal chemotherapy, normothermic and hyperthermic chemoperfusion in a rat model of ascitic ovarian cancer.
Bespalov VG; Alvovsky IK; Tochilnikov GV; Stukov AN; Vyshinskaya EA; Semenov AL; Vasilyeva IN; Belyaeva OA; Kireeva GS; Senchik KY; Zhilinskaya NT; Von JD; Krasilnikova LA; Alexandrov VA; Khromov-Borisov NN; Baranenko DA; Belyaev AM
Int J Hyperthermia; 2018 Aug; 34(5):545-550. PubMed ID: 28893108
[TBL] [Abstract][Full Text] [Related]
11. Expression of gonadotropin-releasing hormone (GnRH) receptor gene is altered by GnRH agonist desensitization in a manner similar to that of gonadotropin beta-subunit genes in normal and castrated rat pituitary.
Lerrant Y; Kottler ML; Bergametti F; Moumni M; Blumberg-Tick J; Counis R
Endocrinology; 1995 Jul; 136(7):2803-8. PubMed ID: 7789305
[TBL] [Abstract][Full Text] [Related]
12. Actions of gonadotropin-releasing hormone analogues in pituitary gonadotrophs and their modulation by ovarian steroids.
Weiss JM; König SJ; Polack S; Emons G; Schulz KD; Diedrich K; Ortmann O
J Steroid Biochem Mol Biol; 2006 Oct; 101(2-3):118-26. PubMed ID: 16891115
[TBL] [Abstract][Full Text] [Related]
13. Luteinizing hormone-releasing hormone (LHRH) inhibits apoptosis induced by cytotoxic agent and UV-light but not apoptosis mediated through CD95 in human ovarian and endometrial cancer cells.
Günthert AR; Gründker C; Böttcher B; Emons G
Anticancer Res; 2004; 24(3a):1727-32. PubMed ID: 15274347
[TBL] [Abstract][Full Text] [Related]
14. A randomized, controlled clinical trial comparing the effects of aromatase inhibitor (letrozole) and gonadotropin-releasing hormone agonist (triptorelin) on uterine leiomyoma volume and hormonal status.
Parsanezhad ME; Azmoon M; Alborzi S; Rajaeefard A; Zarei A; Kazerooni T; Frank V; Schmidt EH
Fertil Steril; 2010 Jan; 93(1):192-8. PubMed ID: 19135657
[TBL] [Abstract][Full Text] [Related]
15. Luteinizing hormone-releasing hormone agonist triptorelin and antagonist cetrorelix inhibit EGF-induced c-fos expression in human gynecological cancers.
Gründker C; Völker P; Schulz KD; Emons G
Gynecol Oncol; 2000 Aug; 78(2):194-202. PubMed ID: 10926802
[TBL] [Abstract][Full Text] [Related]
16. New gonadotropin-releasing hormone glycolipids with direct antiproliferative activity and gonadotropin-releasing potency.
Varamini P; Mansfeld FM; Giddam AK; Steyn F; Toth I
Int J Pharm; 2017 Apr; 521(1-2):327-336. PubMed ID: 28232269
[No Abstract] [Full Text] [Related]
17. [Pharmacological and clinical profile of exemestane (Aromasin), a novel irreversible aromatase inhibitor].
Tahara M; Nomura S; Hashimoto M
Nihon Yakurigaku Zasshi; 2003 Oct; 122(4):345-54. PubMed ID: 14501171
[TBL] [Abstract][Full Text] [Related]
18. [Potentiation of the antitumor activity of dioxadet by antiestrogen para-aminobenzhydrazide in a model of ovarian ascites tumor].
Tret'iakov AV; Kraĭz BO
Vopr Onkol; 1983; 29(12):66-8. PubMed ID: 6666098
[TBL] [Abstract][Full Text] [Related]
19. Luteinizing hormone-releasing hormone induces nuclear factor kappaB-activation and inhibits apoptosis in ovarian cancer cells.
Gründker C; Schulz K; Günthert AR; Emons G
J Clin Endocrinol Metab; 2000 Oct; 85(10):3815-20. PubMed ID: 11061544
[TBL] [Abstract][Full Text] [Related]
20. Premenopausal breast cancer patients treated with a gonadotropin-releasing hormone analog alone or in combination with an aromatase inhibitor: a comparative endocrine study.
Celio L; Martinetti A; Ferrari L; Buzzoni R; Mariani L; Miceli R; Seregni E; Procopio G; Cassata A; Bombardieri E; Bajetta E
Anticancer Res; 1999; 19(3B):2261-8. PubMed ID: 10472341
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
